← All Sponsors
SPONSOR

ZHOU FANGJIAN

Total Trials
1
Recruiting
1
Phases
Phase 3
Conditions studied: Renal Cell CarcinomaNeoadjuvant
NCT05738694 Phase 3
Recruiting

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Renal Cell Carcinoma
China View Trial →